
Trk receptor
Trk receptor inhibitors target the Tropomyosin receptor kinases (Trk), a family of receptor tyrosine kinases that play a significant role in the development and function of the nervous system. Trk receptors are involved in neurotrophin signaling, which is essential for the survival, differentiation, and growth of neurons. Dysregulation of Trk signaling is associated with neurological disorders and certain cancers. At CymitQuimica, we offer Trk receptor inhibitors to support your research in neurobiology, oncology, and neurodegenerative diseases.
Found 59 products of "Trk receptor"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
TrkA-IN-9
CAS:<p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>Formula:C31H32N4O4Color and Shape:SolidMolecular weight:524.61PF-06273340
CAS:<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Formula:C23H22ClN7O3Purity:98% - 98.00%Color and Shape:SolidMolecular weight:479.92NMS-P626
CAS:<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>Formula:C28H35F2N7O4SColor and Shape:SolidMolecular weight:603.68BNN-20
CAS:<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Formula:C20H30O2Color and Shape:SolidMolecular weight:302.45TrkC-IN-1
CAS:<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Formula:C28H20BrN5O2Color and Shape:SolidMolecular weight:538.395ONO-7579
CAS:<p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>Formula:C24H18ClF3N6O4SColor and Shape:SolidMolecular weight:578.95HS-345
CAS:<p>HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.</p>Formula:C19H18N6O2SColor and Shape:SolidMolecular weight:394.45Trk-IN-4
CAS:<p>Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.</p>Formula:C24H23F4N5O4Purity:98.13%Color and Shape:SolidMolecular weight:521.46TrkB-IN-1
CAS:<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Formula:C19H16N2O6Purity:98%Color and Shape:SolidMolecular weight:368.34
